Member Info for ant15

I just look forward to the next trading statement which should be an excellent read Everything is being done to pull this back to its original status its opening Market Cap and beyond in my opinion., and its easily achievable. The technology is just superb you cannot ignore 15 of the major pharma's as clients Years ago a small bio would IPO with just one or the possibility of one. I am totally sold on this company. and that's with 30 years of experience in the industry.

Sorry about the previous posts useful info on IPO price and Market Cap in 2021 taken from ADVFN

$ hours ago AT posted this on X

"Great week on the West Coast of the USA and finally recovered from my jet lag. There continues to be much interest in our platform across the board. Looking forward to starting some amazing partnerships and solving exciting scientific challenges."

https://x.com/ArronTolley/status/1893960158067269968

Timbo003 23 Dec '21 - 04:52

0 3 0

Charts

Intraday chart. Click to open a chart window 6 Month chart. Click to open a chart window

News

28/01/2025 14:56 LSEG_RNS Aptamer Group PLC Issue of Equity in lieu of Director fees

28/01/2025 07:00 LSEG_RNS Aptamer Group PLC Half Year Trading Update

* First day of trading on AIM - December 22nd 2021

* Issue price – 117p

* Capital raised on admission - £10.8m

* Anticipated mkt cap on admission – £80m

* Percentage of securities not in public hands: 85.3%

………………………

Usefuk Links:

Aptamer Group web site

Admissions document

Youtube Channel

Twitter feed

Aptamers (wikipedia)

Antibody mimetics (Wikipedia)

Turner Pope Research note (July 24th 2024)

Turner Pope Research note (Nov 8th 2024)

Timbo003 23 Dec '21 - 04:52

0 3 0

Charts

Intraday chart. Click to open a chart window 6 Month chart. Click to open a chart window

News

28/01/2025 14:56 LSEG_RNS Aptamer Group PLC Issue of Equity in lieu of Director fees

28/01/2025 07:00 LSEG_RNS Aptamer Group PLC Half Year Trading Update

* First day of trading on AIM - December 22nd 2021

* Issue price – 117p

* Capital raised on admission - £10.8m

* Anticipated mkt cap on admission – £80m

* Percentage of securities not in public hands: 85.3%

………………………

Usefuk Links:

Aptamer Group web site

Admissions document

Youtube Channel

Twitter feed

Aptamers (wikipedia)

Antibody mimetics (Wikipedia)

Turner Pope Research note (July 24th 2024)

Turner Pope Research note (Nov 8th 2024)

THE JUSTIFICATION AGAIN;

IPO £1.70 per share MARKET CAP on the day rising to in excess of £100 million . All the work has been done to finesse the technology and now we have the contracts that were all to come at the time of IPO. Troubled times that COVID didn't help BUT despite subsequent placings needed to recover they are now far better positioned than they were at IPO. We are currently MARKET CAP £8 million. Do the Maths use logic and then think of what's in the Pipeline and £250 million MC is so achievable 2 or 3 contracts mature and £500 million is still very realistic . The best AIM opportunity foe certain I'll bang the drum as one who sees the very special case for writing so well of their position and ability to capitalise on their technology 15 of the top 20 Pharma Co's as clients speaks volumes.

This is an 18 month old article but it gives a tremendous flavour for what might happen here Novartis made an upfront payment of $500 million No doubt the discerning will be able to link the technologies.

https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharma

IPO £1.70 per share MARKET CAP on the day rising to in excess of £100 million . All the work has been done to finesse the technology and now we have the contracts that were all to come at the time of IPO. Troubled times that COVID didn't help BUT despite subsequent placings needed to recover they are now far better positioned than they were at IPO. We are currently MARKET CAP £8 million. Do the Maths use logic and then think of what's in the Pipeline and £250 million MC is so achievable 2 or 3 contracts mature and £500 million is still very realistic . The best AIM opportunity foe certain I'll bang the drum as one who sees the very special case for writing so well of their position and ability to capitalise on their technology 15 of the top 20 Pharma Co's as clients speaks volumes.

Further posted on ADVFN that AT was also seen before the offices of Johnson and Johnson Surely easing doubts as with Lilly too that it is not a coincidental post.

Gaining traction soon when others read and realise what's round the corner we will reach the "inflection point" that AT spoke of as being about to happen. What will the price do then is not a mystery only by how much it will soar.

I can't take the credit Someuwin on ADVFN saw it first. I have to imagine that AT would not have done this for any reason than to make others aware of where he had been.! I don't expect a debrief far too many large Pharma's would expect confidentiality from any discussions. But there is a wealth of news just around the corner which can be found if you go back and look for the prompts in their announcements.

Standing outside Eli Lilly building too!

She's always rude Sushi. Its the one reason I don't bother to post here on a regular basis. The News today pathetic The management have a lot of explaining to do not just regurgitating the same old rhetoric. Share price flushed again and again. The opportunities are there the management seemingly incapable of converting them for PYC.

It might be worth noting the CEY was purchased for 2.5 billion with an annual production of circa 430,000 ounces of gold GGP looks to produce circa 400,000 ounces plus december 24 to december 25 but has a market cap of only 1.09 billion Just a point of reference.

Yoglet I personally believe it will move way beyond 8p Lets wait and see.

Ferring for a buy out put your finger in the air see which way the winds blowing and then imagine £250m to £500 million If all three topical studies work its a mind blowing prospect and currently the news is positive on all three fronts. As for share price its currently way undervalued is all we really need to say.

Freddie you're a wee bit rusty here old son. Read the patents that'll give you the very best information. Not easy reads as research rarely is. Just think of the three most topical points that any lay person ( no insult intended at all )can understand

Alzheimer home lateral flow test Market Sector £ or $ billions.

Malodour market sector £35 billion plus Unilever has 30% share

SiRNA . A Vector for drug delivery in conjugate form with AZ's SiRNA drugs market sector Billions £ or $

And if anyone has not understood imagine that either of AZ or Unilever might buy the company.

It's really or one needs to know when forecasting the potential share price

Well if that doesn't move the share price nothing will An excellent RNS everything heading in the right direction

I have researched the opportunity over 9 months and bought in on the vey strong belief that announcements of progress with Unilver a massive market opportunity and AZ likewise will take this swiftly to 5p a share this is a x10 multiple. However If announcements lead to a buy out we could be looking at 15p plus a share and possibly as high as this on revenue generation from either of the two already mentioned without others of which there are several. You can ignore my post if you wish but this is possibly one of the best opportunities for significant returns in 2025.

The first collaboration that demonstrates the feasibility of their technology could result in an offer for the company that might well result in a bidding war. AZ and Unilever are both very acquisitive and the technology offers transformational returns. Look at the IPO price of this based on the technology not as a per share but for the company and this could be a £250 million plus buy out.

Laura I emailed PYC several months ago and AVACTA too suggesting they should talk Who knows? Ant